Tumor antigen useful in diagnosis and therapy of prostate and colon cancer

US7037667B1 · kind B1 · utility

Assignee

• Latency, LLC · US

Inventors

• Daniel Afar · Santa Monica, US
• Rene S. Hubert · Los Angeles, US
• Kahan Leong · El Segundo, US
• Arthur B. Raitano · Los Angeles, US
• Douglas Saffran · Los Angeles, US
• Stephen Chappell Mitchell · Santa Monica, US
• Aya Jakobovits · Beverly Hills, US
• Mary Faris · Los Angeles, US
• Igor Vivanco · Los Angeles, US

Key dates

• Filing date: Jul 12, 2000
• Grant date: May 2, 2006
• Expiry date: Oct 20, 2020

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/95
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-related, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. 1). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth. The invention further provides various therapeutic compositions and strategies for treating prostate cancer, including particularly, 20P1F12/TMPRSS2 polypeptide and anti-20P1F12/TMPRSS2 antibody therapy met…